MedTrace Logo

Male Hormonal Contraceptive Development-ACY-5

NCT00161447 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2008-09-19

No results posted yet for this study

Summary

The purpose of this research study is to help in the development of male contraception (birth control).

Conditions

  • Contraception

Interventions

DRUG

Acyline

Acyline 300 mcg/kg SQ every 2 weeks for 12 weeks

DRUG

Testosterone Gel

Testosterone Gel (10 g daily

DRUG

Depo-Medroxyprogesterone

DMPA (injected into muscle) Day 0 \& month 3

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • CONRAD

    collaborator OTHER

  • University of Washington

    lead OTHER

Principal Investigators

  • William J Bremner, MD, PhD · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2006-04-30
Completion
2006-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00161447 on ClinicalTrials.gov